文献速递衰弱、肌少症与跌倒老年慢病共病管理

衰弱与抗凝治疗在老年房颤患者中的关系:EUROSAF研究

Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study.
PubMed 文献 · Age Ageing · 2023-01-01

EUROSAF研究为欧洲多中心前瞻性研究,纳入2022例≥65岁非瓣膜性房颤住院患者,用多维预后指数(MPI)评估衰弱程度,随访12个月。结果显示,与未用抗凝药者相比,维生素K拮抗剂(HR=0.74)和直接口服抗凝药(DOACs,HR=0.46)均降低死亡风险,且DOACs降低血管事件风险(HR=0.55),疗效独立于衰弱状态,不增加出血风险。

要点

  • DOACs降低死亡风险(HR=0.46)和血管事件风险(HR=0.55)。
  • 抗凝疗效独立于衰弱状态,且不增加出血风险。
  • 建议对老年房颤患者使用抗凝治疗,尤其是DOACs。

核心结论

  • 抗凝治疗尤其是DOACs与老年房颤患者死亡率降低相关,且不增加出血事件风险,提示应重视老年房颤患者的抗凝治疗。

研究设计与样本

  • 欧洲多中心前瞻性研究,纳入2022例≥65岁非瓣膜性房颤住院患者,随访12个月。

主要发现

  • 与未用抗凝药者(n=823)相比,维生素K拮抗剂(n=450)死亡风险降低(HR=0.74;95%CI:0.59-0.93)。
  • DOACs(n=749)死亡风险降低更明显(HR=0.46;95%CI:0.37-0.57)。
  • 仅DOACs组血管事件风险显著降低(HR=0.55;95%CI:0.31-0.97)。
  • DOACs疗效独立于衰弱状态。
  • 胃肠道出血和出血性卒中风险在不同抗凝治疗和MPI值间无差异。

关键数值与推荐

  • MPI用于将参与者分为健壮、衰弱前期或衰弱。
  • 主要结局为死亡率,次要结局为血管事件(包括缺血性心脏病或缺血性卒中、出血性卒中或胃肠道出血)。

临床怎么用

  • 对老年房颤患者应考虑抗凝治疗,尤其是DOACs,无需因衰弱而排除抗凝。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Literature regarding anticoagulants in older people affected by atrial fibrillation (AF) is limited to retrospective studies, poorly considering the importance of multidimensional frailty. The main objective of this study is to evaluate in hospitalised older persons with AF the benefit/risk ratio of the anticoagulant treatments, considering the severity of frailty, determined by the multidimensional prognostic index (MPI). METHODS: In this European, multicentre, prospective study, older hospitalised patients (≥65 years) with non-valvular AF were followed-up for 12 months. Anticoagulants' use at discharge ascertained using medical records. MPI was calculated using tools derived from comprehensive geriatric assessment, classifying participants in robust, pre-frail or frail. Mortality (primary outcome); vascular events, including ischemic heart disease or ischemic stroke, hemorrhagic stroke or gastrointestinal bleedings (secondary outcomes). RESULTS: 2,022 participants (mean age 82.9 years; females 56.6%) were included. Compared with people not taking anticoagulants (n = 823), people using vitamin K antagonists (n = 450) showed a decreased risk of mortality (hazard ratio, HR = 0.74; 95% CI: 0.59-0.93), more pronounced in patients using direct oral anticoagulants (DOACs) (n = 749) (HR = 0.46; 95% CI: 0.37-0.57). Only people taking DOACs reported a significantly lower risk of vascular events (HR = 0.55; 95% CI: 0.31-0.97). The efficacy of DOACs was present independently from frailty status. The risk of gastrointestinal bleedings and hemorrhagic stroke did not differ based on the anticoagulant treatments and by MPI values. CONCLUSIONS: Anticoagulant treatment, particularly with DOACs, was associated with reduced mortality in older people, without increasing the risk of hemorrhagic events, overall suggesting the importance of treating with anticoagulants older people with AF.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Pilotto A, Veronese N, Polidori MC, et al. Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study. Age Ageing. 2023. PMID: 39248098. doi:10.1093/ageing/afad216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。